Patrick P J Phillips

List of Publications by Year
in descending order

91 papers	5,307 citations	117625 34 h-index	88630 70 g-index
95 all docs	95 docs citations	95 times ranked	5457 citing authors

#	Article	IF	Citations
1	Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease. New England Journal of Medicine, 2012, 366, 893-903.	27.0	626
2	Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis. New England Journal of Medicine, 2014, 371, 1577-1587.	27.0	551
3	High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis. New England Journal of Medicine, 2014, 371, 1599-1608.	27.0	383
4	High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infectious Diseases, The, 2017, 17, 39-49.	9.1	294
5	A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. New England Journal of Medicine, 2019, 380, 1201-1213.	27.0	275
6	A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1058-1065.	5.6	260
7	Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. New England Journal of Medicine, 2021, 384, 1705-1718.	27.0	259
8	A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nature Medicine, 2018, 24, 1708-1715.	30.7	219
9	Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respiratory Medicine,the, 2013, 1, 462-470.	10.7	151
10	Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry, 2011, 26, 812-817.	2.7	126
11	Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurology, The, 2015, 14, 1171-1181.	10.2	124
12	Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials, 2014, 15, 353.	1.6	110
13	Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals. BMJ Open, 2016, 6, e012594.	1.9	105
14	Molecular Bacterial Load Assay, a Culture-Free Biomarker for Rapid and Accurate Quantification of Sputum Mycobacterium tuberculosis Bacillary Load during Treatment. Journal of Clinical Microbiology, 2011, 49, 3905-3911.	3.9	97
15	The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. Clinical Infectious Diseases, 2018, 67, 34-41.	5.8	80
16	Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respiratory Medicine,the, 2018, 6, 265-275.	10.7	80
17	Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 1558-1566.	3.0	77
18	An Evaluation of Culture Results during Treatment for Tuberculosis as Surrogate Endpoints for Treatment Failure and Relapse. PLoS ONE, 2013, 8, e63840.	2.5	69

#	Article	IF	Citations
19	The Molecular Bacterial Load Assay Replaces Solid Culture for Measuring Early Bactericidal Response to Antituberculosis Treatment. Journal of Clinical Microbiology, 2014, 52, 3064-3067.	3.9	62
20	Principles for designing future regimens for multidrug-resistant tuberculosis. Bulletin of the World Health Organization, 2014, 92, 68-74.	3.3	60
21	Testing many treatments within a single protocol over 10â€‰years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. Clinical Trials, 2017, 14, 451-461.	1.6	59
22	Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis. Journal of Infectious Diseases, 2012, 205, S250-S257.	4.0	58
23	The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations. Journal of Antimicrobial Chemotherapy, 2015, 70, 448-455.	3.0	58
24	Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trial. BMC Medicine, 2017, 15, 71.	5.5	57
25	Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials. BMC Medicine, 2016, 14, 19.	5.5	56
26	Tuberculosis Biomarker and Surrogate Endpoint Research Roadmap. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 972-979.	5.6	52
27	Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis, 2010, 90, 301-305.	1.9	49
28	Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis Molecular Bacterial Load Assay. Thorax, 2020, 75, 606-608.	5.6	49
29	Costâ€effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the) Tj ETQq1 1 0.784314 rgBT /Overloc	2.7	48
30	Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC Medicine, 2018, 16, 46.	5.5	46
31	DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease â€“ a multicentre RCT. Trials, 2009, 10, 57.	1.6	44
32	Impact of Cotrimoxazole on Carriage and Antibiotic Resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-Infected Children in Zambia. Antimicrobial Agents and Chemotherapy, 2010, 54, 3756-3762.	3.2	40
33	Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). Tuberculosis, 2008, 88, S85-S92.	1.9	38
34	High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. Contemporary Clinical Trials, 2020, 90, 105938.	1.8	36
35	A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis. BMC Medical Research Methodology, 2013, 13, 139.	3.1	34
36	Proposals on Kaplanâ€“Meier plots in medical research and a survey of stakeholder views: KMunicate. BMJ Open, 2019, 9, e030215.	1.9	33

#	Article	IF	Citations
37	Increased bactericidal activity but dose-limiting intolerability at 50â€…mgÂ·kg^{â^'1} rifampicin. European Respiratory Journal, 2021, 58, 2000955.	6.7	32
38	A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP). BMC Medicine, 2016, 14, 51.	5.5	25
39	Challenges in the clinical assessment of novel tuberculosis drugs. Advanced Drug Delivery Reviews, 2016, 102, 116-122.	13.7	25
40	The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia. PLoS ONE, 2016, 11, e0152761.	2.5	23
41	Rethinking non-inferiority: a practical trial design for optimising treatment duration. Clinical Trials, 2018, 15, 477-488.	1.6	20
42	Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape. PLoS Medicine, 2019, 16, e1002767.	8.4	20
43	Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults. International Journal of Tuberculosis and Lung Disease, 2016, 20, 290-294.	1.2	18
44	Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	18
45	Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infectious Diseases, The, 2010, 10, 69-70.	9.1	17
46	Shortening treatment of tuberculosis: lessons from fluoroquinolone trials. Lancet Infectious Diseases, The, 2015, 15, 141-143.	9.1	17
47	An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial. Trials, 2017, 18, 563.	1.6	17
48	Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1086-1096.	5.6	17
49	When inferiority meets non-inferiority: Implications for interim analyses. Clinical Trials, 2012, 9, 605-609.	1.6	16
50	Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes. Trials, 2016, 17, 309.	1.6	16
51	Toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC Infectious Diseases, 2018, 18, 317.	2.9	16
52	Optimising pyrazinamide for the treatment of tuberculosis. European Respiratory Journal, 2021, 58, 2002013.	6.7	15
53	Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial. Bulletin of the World Health Organization, 2020, 98, 306-314.	3.3	15
54	Randomized clinical trials to identify optimal antibiotic treatment duration. Trials, 2013, 14, 88.	1.6	14

#	Article	IF	Citations
55	Experiences of living with varicose veins: A systematic review of qualitative research. Journal of Clinical Nursing, 2019, 28, 1085-1099.	3.0	14
56	Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance. European Respiratory Journal, 2019, 54, 1900982.	6.7	14
57	Protein binding of rifampicin is not saturated when using high-dose rifampicin. Journal of Antimicrobial Chemotherapy, 2019, 74, 986-990.	3.0	13
58	Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis. BMC Medicine, 2017, 15, 192.	5.5	12
59	A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens. BMC Medicine, 2017, 15, 207.	5.5	12
60	Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS Trial. Clinical Infectious Diseases, 2022, 75, 1594-1601.	5.8	12
61	Is a 4-month regimen adequate to cure patients with non-cavitary tuberculosis and negative cultures at 2 months? [Short communication]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 807-809.	1.2	10
62	Mycobactericidal Effects of Different Regimens Measured by Molecular Bacterial Load Assay among People Treated for Multidrug-Resistant Tuberculosis in Tanzania. Journal of Clinical Microbiology, 2021, 59, .	3.9	10
63	Treatment of pulmonary tuberculosis. Current Opinion in Pulmonary Medicine, 2013, 19, 273-279.	2.6	9
64	Q feverâ€"the superstition of avoiding the word â€œquietâ€•as a coping mechanism: randomised controlled non-inferiority trial. BMJ, The, 2019, 367, l6446.	6.0	9
65	Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. Implementation Science, 2020, 15, 65.	6.9	8
66	A Step toward an Optimized Rifampin Dose Completed. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 525-526.	5.6	7
67	Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. European Respiratory Journal, 2016, 47, 1591-1592.	6.7	7
68	Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 598-605.	5.6	7
69	Biomarkers and Surrogate End Points in Clinical Trials of Tuberculosis Treatment. Journal of Infectious Diseases, 2007, 196, 648-649.	4.0	6
70	Challenges of Phase III study design for trials of new drug regimens for the treatment of TB. Future Medicinal Chemistry, 2010, 2, 1273-1282.	2.3	6
71	A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials. Trials, 2021, 22, 515.	1.6	6
72	Completion of isoniazidâ€“rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectivenessâ€“implementation randomized trial. PLoS Medicine, 2021, 18, e1003875.	8.4	6

#	Article	IF	Citations
73	IMPACT OF MOLECULAR GENETIC METHODS ON THE INITIATION OF CHEMOTHERAPY IN MULTIPLE DRUG RESISTANTTUBERCULOSIS PATIENTS IN ARKHANGELSK REGION. Tuberculosis and Lung Diseases, 2017, 95, 10-17.	0.7	5
74	Clinical Impact of the Line Probe Assay and XpertÂ® MTB/RIF Assay in the Presumptive Diagnosis of Drug-Resistant Tuberculosis in Brazil: A Pragmatic Clinical Trial. Revista Da Sociedade Brasileira De Medicina Tropical, 2022, 55, e0191.	0.9	3
75	An Analysis With Serious Flaws. Clinical Infectious Diseases, 2013, 57, 1064-1065.	5.8	2
76	World TB Day 2016: an interview with leading experts in tuberculosis research. BMC Medicine, 2016, 14, 55.	5.5	2
77	Setting Tuberculosis Regimen Development on a Firm Foundation. Clinical Infectious Diseases, 2017, 65, 55-56.	5.8	2
78	Feasibility of Direct Sputum Molecular Testing for Drug Resistance as Part of Tuberculosis Clinical Trials Eligibility Screening. Diagnostics, 2019, 9, 56.	2.6	2
79	Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine. Clinical Infectious Diseases, 2021, , .	5.8	2
80	Tuberculosis screening improves preventive therapy uptake (TB SCRIPT) trial among people living with HIV in Uganda: a study protocol of an individual randomized controlled trial. Trials, 2022, 23, 399.	1.6	2
81	Short Intensified Treatment in Children with Drug-susceptible Tuberculous Meningitis. Pediatric Infectious Disease Journal, 2014, 33, 993.	2.0	1
82	Comments on â€˜A modest proposal for dropping poor arms in clinical trialsâ€™ by Proschan and Dodd. Statistics in Medicine, 2015, 34, 2678-2679.	1.6	1
83	Reducing relapse in tuberculosis treatment. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1263-1264.	1.2	1
84	OP27 Patient-Reported Outcome Measures In Carotid Artery Revascularization. International Journal of Technology Assessment in Health Care, 2017, 33, 12-13.	0.5	1
85	Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status. BMC Pulmonary Medicine, 2019, 19, 152.	2.0	1
86	STREAM: a pragmatic and explanatory trial for MDR-TB treatment. Lancet Infectious Diseases, The, 2019, 19, 575-576.	9.1	1
87	Noninferiority Trials. , 2021, , 1-28.		1
88	Reply to Dodd and Proschan. Journal of Infectious Diseases, 2013, 207, 544-545.	4.0	0
89	Safe and effective treatment for patients with isoniazid drug resistance. International Journal of Tuberculosis and Lung Disease, 2015, 19, 494-495.	1.2	0
90	Reply to Swindells et al.: Trials of Tuberculosis-Preventive Therapy in People with HIV Infection. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 305-306.	5.6	0

#	Article	IF	Citations
91	MOVER approximated CV: A tool for quantifying precision in ratiometric droplet digital PCR assays. Journal of Pharmaceutical and Biomedical Analysis, 2022, 212, 114664.	2.8	0